SATHGEN

THERAPEUTICS

State-of-the-art science for the hardest-to-treat cancers

We are seeking strategic partners for out-licensing, co-development and investment for our exciting lead molecule that has shown robust safety and efficacy against one of the most vicious of cancers - TNBC (triple negative breast cancer).

Our Pipeline

With a pipeline of more than 40 compounds, we are building a diversified portfolio aimed at addressing critical unmet need in cancer and other indications.

Our lead program targets Triple Negative Breast Cancer (TNBC) – an aggressive and underserved cancer subtype affecting over 340,000 patients globally each year. Limited therapeutic options contribute to poor prognosis and nearly 200,000 annual deaths worldwide.

MSP008-22, is a first-in-class therapeutic with a novel mechanism of action. It has demonstrated compelling efficacy in preclinical cancer models and an outstanding safety profile in clinical trials. Patent protection has been granted in multiple jurisdictions, laying a strong foundation for global commercialization.

With TNBC representing a multibillion-dollar market opportunity and growing interest in innovative oncology solutions, MSP008-22 is well-positioned to be a game-changer—not only for TNBC but for other difficult-to-treat cancers in our pipeline.

Drug class and Indications

MSP

MSP008-22 is the lead candidate of five MSP-derived molecules currently in development. It has shown robust safety in healthy humans and patients with solid tumors in Phase 1 clinical trials. It has also shown exceptional safety profile in preclinical studies across multiple cancer types and exhibits potential antiviral activity against SARS-CoV-2.

SBGBL

Similar to the MSP group, SBGBL was selected from 116 candidates based on its safety and efficacy. It has demonstrated anti-cancer activity across multiple cancers, including triple-negative breast, prostate, oral, glioblastoma, hepatic, cervical, colon, and lung.

LSPGBL

This SAR-positive molecule inhibits cancer stem cell activity by targeting survival pathways. Twelve lead LSP-derived candidates have been identified with strong anti-cancer activity and no observed toxicity across multiple cancers, including triple-negative breast, prostate, oral, glioblastoma, hepatic, cervical, colon, and lung.

METGBL

This SAR-active, potential best-in-class molecule was developed from two tyrosine kinase inhibitors. Twenty-six MET-derived candidates are currently under evaluation for toxicity and anti-cancer efficacy.